UB Paderborn / Katalog / Suche / in CDI

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A

The New England journal of medicine, 2023-02, Vol.388 (8), p.694-705

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective

Critical reviews in oncology/hematology, 2022-06, Vol.174, p.103678-103678, Article 103678

2022

Link zum Volltext

Verfügbarkeit prüfen

Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature

Haemophilia : the official journal of the World Federation of Hemophilia, 2023-01, Vol.29 (1), p.33-44

2023

Link zum Volltext

Verfügbarkeit prüfen

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027

Haemophilia : the official journal of the World Federation of Hemophilia, 2020-07, Vol.26 (4), p.e201-e204

2020

Link zum Volltext

Verfügbarkeit prüfen

The impact of obesity on chronic pain in patients with haemophilia: A multicentre retrospective analysis

Haemophilia : the official journal of the World Federation of Hemophilia, 2024-03, Vol.30 (2), p.567-570

2024

Link zum Volltext

Verfügbarkeit prüfen

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

Thrombosis and haemostasis, 2021-08, Vol.121 (8), p.1079

2021

Link zum Volltext

Verfügbarkeit prüfen

Interim analyses of the multinational real‐world prospective cohort HEM‐POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A

European journal of haematology, 2024-02, Vol.112 (2), p.286-295

2024

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial

Thrombosis research, 2019-11, Vol.183, p.13-19

2019

Link zum Volltext

Verfügbarkeit prüfen

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-05, Vol.27 (3), p.e347-e356

2021

Link zum Volltext

Verfügbarkeit prüfen

Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A

Journal of thrombosis and haemostasis, 2024-07, Vol.22 (7), p.1880-1893

2024

Link zum Volltext

Verfügbarkeit prüfen

Plasma exchange to remove heparin-induced thrombocytopenia antibodies and the use of heparin during cardiopulmonary bypass in critically ill cardiac patients

The Journal of heart and lung transplantation, 2018-08, Vol.37 (8), p.1038-1040

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of BAY 94–9027, an extended‐half‐life factor VIII, during minor surgical procedures in patients with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-07, Vol.27 (4), p.e559-e562

2021

Link zum Volltext

Verfügbarkeit prüfen

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-11, Vol.25 (6), p.1011-1019

2019

Link zum Volltext

Verfügbarkeit prüfen

Opioid exposure in haemophilia patients is common and underreported

Haemophilia : the official journal of the World Federation of Hemophilia, 2020-03, Vol.26 (2), p.251-256

2020

Link zum Volltext

Verfügbarkeit prüfen

Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients

Thrombosis and haemostasis, 2002-10, Vol.88 (4), p.568

2002

Link zum Volltext

Verfügbarkeit prüfen

Anti–Factor Xa and Activated Partial Thromboplastin Time Measurements for Heparin Monitoring in Mechanical Circulatory Support

JACC. Heart failure, 2015-04, Vol.3 (4), p.314-322

2015

Link zum Volltext

Verfügbarkeit prüfen

A laparoscopic approach to address massive splenomegaly, symptomatic cholelithiasis, and a planned postoperative pregnancy: A case report

Clinical case reports, 2023-01, Vol.11 (1), p.e6831-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-11, Vol.27 (6), p.911-920

2021

Link zum Volltext

Verfügbarkeit prüfen

Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders

Journal of blood medicine, 2021-01, Vol.12, p.897-911

2021

Link zum Volltext

Verfügbarkeit prüfen

Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia

Expert review of hematology, 2023-03, Vol.16 (sup1), p.19-37

2023

Link zum Volltext

Verfügbarkeit prüfen

Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice

The Journal of clinical investigation, 2009-07, Vol.119 (7), p.2086-2099

2009

Link zum Volltext

Verfügbarkeit prüfen

Is prophylaxis required for delivery in women with factor VII deficiency?

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-11, Vol.19 (6), p.827-832

2013

Link zum Volltext

Verfügbarkeit prüfen

Management of Bleeding Associated with Dabigatran and Rivaroxaban: A Survey of Current Practices

Thrombosis research, 2013-08, Vol.132 (2), p.e161-e163

2013

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study

Therapeutic advances in hematology, 2023-01, Vol.14, p.20406207231166779-20406207231166779

2023

Link zum Volltext

Verfügbarkeit prüfen

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study

Journal of clinical medicine, 2021-12, Vol.10 (24), p.5959

2021

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A

Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: A critical review from the physician's perspective

Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027

The impact of obesity on chronic pain in patients with haemophilia: A multicentre retrospective analysis

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

Interim analyses of the multinational real‐world prospective cohort HEM‐POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A

Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study

Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A

Plasma exchange to remove heparin-induced thrombocytopenia antibodies and the use of heparin during cardiopulmonary bypass in critically ill cardiac patients

Safety and efficacy of BAY 94–9027, an extended‐half‐life factor VIII, during minor surgical procedures in patients with severe haemophilia A

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

Opioid exposure in haemophilia patients is common and underreported

Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients

Anti–Factor Xa and Activated Partial Thromboplastin Time Measurements for Heparin Monitoring in Mechanical Circulatory Support

A laparoscopic approach to address massive splenomegaly, symptomatic cholelithiasis, and a planned postoperative pregnancy: A case report

PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors

Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders

Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia

Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice

Is prophylaxis required for delivery in women with factor VII deficiency?

Management of Bleeding Associated with Dabigatran and Rivaroxaban: A Survey of Current Practices

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study

Suchergebnisse filtern